HIGHLIGHTS
- who: David R. Lally from the (UNIVERSITY) have published the article: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies, in the Journal: (JOURNAL) of 21/05/2022
- what: The aim of the current post-hoc analysis is to compare the outcomes of brolucizumab 6 mg and aflibercept 2 mg treatment on BCVA and central subfield thickness (CST) in patients with early persistent retinal fluid from HAWK and HARRIER over the 96week study period. The primary reasons for discontinuation in the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.